including: randomization and supply management system (IRT), electronic data collection system (EDC), subject compliance management system (CnR), solutions for closed-loop drug supply management, etc.; we also provide consulting services based on risk monitoring RBM, such as clinical project management and clinical system implementation. It plays an important supporting role in the strategy of going out for the domestic customers and coming in for the foreign customers, providing efficient and high-quality innovative products and solutions.
1000000+
Subjects
40000+
Users
2000+
Institutions
1000+
Projects
70+
Global Projects
1000+
Cities
6626621+
Drug Management
50+
Audits
For experience in IRT and drug supply management, we will not hesitant to choose Shanhu in the next study again.
10.Shanhu Health has completed all the works successfully and efficiently and achieved the important milestone events, and we will cooperate with Shanhu Health for other projects in the future.
It helped us meet the data and compliance requirements of the regulatory department in the global projects, and we were together to complete many impossible tasks.
In a COVID-19 emergency project, Shanhu team actively cooperated with the schedule and actively promoted project progress while providing very professional solutions to help the project to launch quickly.
Shanhu has a great team, I love to work with them. During the especially difficult period of epidemic, we worked together to go through all the difficulties with rich experience and amazing efficiency.
On April 29, 2021, Camrelizumab was approved by NMPA for treatment of nasopharyngeal carcinoma (NPC), in patients with advanced nasopharyngeal carcinoma whose disease has progressed or is intolerable after prior second-line chemotherapy or higher.
In June of the same year, another piece of news of victory was reported for Camrelizumab, which was approved by NMPA for first-line treatment of patients with locally recurrent or metastatic nasopharyngeal carcinoma in combination with cisplatin and gemcitabine. This is the world’s first PD-1 drug approved for first-line nasopharyngeal carcinoma indications. This is the 6th indication for which Camrelizumab has been approved, following Hodgkin's lymphoma, liver cancer, lung cancer, esophageal squamous carcinoma, and second-line and higher nasopharyngeal carcinoma.
The Sabin strain of inactivated poliomyelitis vaccine (“sIPV”) developed by Sinovac Biotech Co., Ltd. has obtained the drug registration approval issued by National Medical Products Administration on July 12, 2021, and it would be supplied to the market within the year.
SINOVAC's sIPV is an inactivated vaccine, which may not pose a risk of paralysis (VAPP) throughout the course of vaccination, and the inoculator may not excrete active poliovirus into the external environment through the digestive tract, so there is no risk of morbidity due to the survival and mutation of the vaccine strain in the external environment.
Since the beginning of developing sIPV, SINOVAC has focused on the global polio eradication initiative, applying the world-leading technology and using the international standards to develop and manufacture the vaccine. The vaccine contains no preservatives or antibiotics, thus reducing the risk of occurrence of associated adverse reactions.
Contact Us
